NO20065879L - Bisykliske heterosykler som HIV-integraseinhibitorer - Google Patents
Bisykliske heterosykler som HIV-integraseinhibitorerInfo
- Publication number
- NO20065879L NO20065879L NO20065879A NO20065879A NO20065879L NO 20065879 L NO20065879 L NO 20065879L NO 20065879 A NO20065879 A NO 20065879A NO 20065879 A NO20065879 A NO 20065879A NO 20065879 L NO20065879 L NO 20065879L
- Authority
- NO
- Norway
- Prior art keywords
- hiv integrase
- integrase inhibitors
- bicyclic heterocycles
- hiv
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57551304P | 2004-05-28 | 2004-05-28 | |
US60337104P | 2004-08-20 | 2004-08-20 | |
US11/126,891 US7176196B2 (en) | 2004-05-28 | 2005-05-11 | Bicyclic heterocycles as HIV integrase inhibitors |
PCT/US2005/016473 WO2005118593A1 (en) | 2004-05-28 | 2005-05-12 | Bicyclic heterocycles as hiv integrase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065879L true NO20065879L (no) | 2007-02-20 |
Family
ID=35456854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065879A NO20065879L (no) | 2004-05-28 | 2006-12-19 | Bisykliske heterosykler som HIV-integraseinhibitorer |
Country Status (27)
Country | Link |
---|---|
US (2) | US7176196B2 (sr) |
EP (1) | EP1749011B1 (sr) |
JP (1) | JP4874959B2 (sr) |
KR (1) | KR101097623B1 (sr) |
AR (1) | AR049124A1 (sr) |
AT (1) | ATE412656T1 (sr) |
AU (1) | AU2005250356C1 (sr) |
BR (1) | BRPI0511623A (sr) |
CA (1) | CA2568356C (sr) |
CY (1) | CY1110266T1 (sr) |
DE (1) | DE602005010690D1 (sr) |
DK (1) | DK1749011T3 (sr) |
ES (1) | ES2315875T3 (sr) |
HK (1) | HK1107343A1 (sr) |
HR (1) | HRP20090005T3 (sr) |
IL (1) | IL179455A (sr) |
MX (1) | MXPA06013835A (sr) |
NO (1) | NO20065879L (sr) |
NZ (1) | NZ551282A (sr) |
PE (1) | PE20060242A1 (sr) |
PL (1) | PL1749011T3 (sr) |
PT (1) | PT1749011E (sr) |
RS (1) | RS50700B (sr) |
RU (1) | RU2381228C2 (sr) |
SI (1) | SI1749011T1 (sr) |
TW (1) | TWI366567B (sr) |
WO (1) | WO2005118593A1 (sr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
US7939537B2 (en) | 2005-10-04 | 2011-05-10 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HIV integrase inhibitors |
US7902182B2 (en) * | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2007064316A1 (en) * | 2005-11-30 | 2007-06-07 | Bristol-Myers Squibb Company | Bicyclic heterocycles as hiv integrase inhibitors |
WO2007064502A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide |
US20070129379A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
US7897593B2 (en) * | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
JP2009543865A (ja) * | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド | ピリジノンジケト酸:併用療法におけるhiv複製の阻害剤 |
US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US8129398B2 (en) * | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7968541B2 (en) * | 2008-03-27 | 2011-06-28 | Bristol-Myers Squibb Company | Crystalline form of N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-C][1,4]-oxazine-2-carboxamide, sodium salt monohydrate |
BRPI0920605A8 (pt) * | 2008-10-06 | 2016-04-26 | Merck Sharp & Dohme | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
CN102574854B (zh) | 2009-10-13 | 2014-04-16 | 伊兰科动物健康爱尔兰有限公司 | 大环整合酶抑制剂 |
US8383639B2 (en) * | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MX2012006485A (es) | 2009-12-07 | 2012-08-23 | Univ Georgia | Piridinon hidroxiclicopentil carboxamidas: inhibidores de la integrasa del vih con aplicaciones terapeuticas. |
NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
EP2552923B1 (en) | 2010-04-02 | 2014-03-26 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
CN104086528A (zh) | 2010-07-15 | 2014-10-08 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
JP2015508417A (ja) * | 2012-01-26 | 2015-03-19 | クロ コンサルティング リミテッド | 神経変性障害を治療するためのジアジリジン |
US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
ME02977B (me) | 2013-05-17 | 2018-10-20 | Merck Sharp & Dohme | Fuzionisana triciklicna heterociklicna jedinjenja као inhibiтori hiv integraze |
US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
WO2015048363A1 (en) | 2013-09-27 | 2015-04-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
EP3389380B1 (en) | 2015-12-15 | 2021-07-21 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
EP3573984A4 (en) | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS |
WO2021050555A1 (en) * | 2019-09-10 | 2021-03-18 | X-Chem, Inc. | Compositions and uses thereof |
CN113912622B (zh) * | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL161337A0 (en) | 2001-10-26 | 2004-09-27 | Angeletti P Ist Richerche Bio | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
DK1441734T3 (da) | 2001-10-26 | 2007-06-11 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase |
WO2004002406A2 (en) * | 2002-06-26 | 2004-01-08 | Bristol-Myers Squibb Company | Bicyclic pyrimidinones as coagulation cascade inhibitors |
KR20050087865A (ko) | 2002-12-27 | 2005-08-31 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | HIV 인테그라제 억제제로서 유용한테트라하이드로-4H-피리도[1,2-a]피리미딘 및 관련화합물 |
AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
KR20070085702A (ko) | 2004-12-03 | 2007-08-27 | 머크 앤드 캄파니 인코포레이티드 | Ugt1a1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도 |
CN101146811B (zh) | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
-
2005
- 2005-05-11 US US11/126,891 patent/US7176196B2/en active Active
- 2005-05-12 BR BRPI0511623-6A patent/BRPI0511623A/pt not_active IP Right Cessation
- 2005-05-12 RS RSP-2008/0569A patent/RS50700B/sr unknown
- 2005-05-12 NZ NZ551282A patent/NZ551282A/en not_active IP Right Cessation
- 2005-05-12 RU RU2006146970/04A patent/RU2381228C2/ru not_active IP Right Cessation
- 2005-05-12 AT AT05750075T patent/ATE412656T1/de active
- 2005-05-12 JP JP2007515142A patent/JP4874959B2/ja not_active Expired - Fee Related
- 2005-05-12 DE DE602005010690T patent/DE602005010690D1/de active Active
- 2005-05-12 ES ES05750075T patent/ES2315875T3/es active Active
- 2005-05-12 WO PCT/US2005/016473 patent/WO2005118593A1/en active Application Filing
- 2005-05-12 EP EP05750075A patent/EP1749011B1/en active Active
- 2005-05-12 MX MXPA06013835A patent/MXPA06013835A/es active IP Right Grant
- 2005-05-12 SI SI200530481T patent/SI1749011T1/sl unknown
- 2005-05-12 PT PT05750075T patent/PT1749011E/pt unknown
- 2005-05-12 DK DK05750075T patent/DK1749011T3/da active
- 2005-05-12 AU AU2005250356A patent/AU2005250356C1/en not_active Ceased
- 2005-05-12 CA CA2568356A patent/CA2568356C/en not_active Expired - Fee Related
- 2005-05-12 PL PL05750075T patent/PL1749011T3/pl unknown
- 2005-05-25 TW TW094117105A patent/TWI366567B/zh not_active IP Right Cessation
- 2005-05-27 AR ARP050102187A patent/AR049124A1/es not_active Application Discontinuation
- 2005-05-30 PE PE2005000602A patent/PE20060242A1/es not_active Application Discontinuation
-
2006
- 2006-08-16 US US11/505,149 patent/US7511037B2/en active Active
- 2006-11-21 IL IL179455A patent/IL179455A/en not_active IP Right Cessation
- 2006-12-19 NO NO20065879A patent/NO20065879L/no not_active Application Discontinuation
- 2006-12-27 KR KR1020067027455A patent/KR101097623B1/ko not_active IP Right Cessation
-
2007
- 2007-11-26 HK HK07112893.6A patent/HK1107343A1/xx not_active IP Right Cessation
-
2009
- 2009-01-07 HR HR20090005T patent/HRP20090005T3/xx unknown
- 2009-01-19 CY CY20091100068T patent/CY1110266T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065879L (no) | Bisykliske heterosykler som HIV-integraseinhibitorer | |
NO20082135L (no) | HIV integrase inhibitorer | |
NO20081935L (no) | HIV-integraseinhibitorer | |
NO20080797L (no) | Bicykliske heterocykler som HIV Integrase inhibitorer | |
WO2008002959A3 (en) | Hiv integrase inhibitors | |
WO2007059125A3 (en) | Hiv integrase inhibitors | |
NO20065443L (no) | HIV-Integraseinhibitorer: Sykliske pyrimidinonforbindelser | |
MX2010009995A (es) | Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana. | |
NO20090202L (no) | Prolylhydroksylaseinhibitorer | |
WO2004096128A3 (en) | Hiv integrase inhibitors | |
NO20070137L (no) | Heterocykliske antivirale forbindelser | |
WO2005115398A3 (en) | Hiv integrase inhibitors | |
NO20083585L (no) | Hetero-bisykliske antivirale forbindelser | |
DE602006020152D1 (de) | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion | |
TW200635918A (en) | Pharmaceutical compounds | |
NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
GB0612423D0 (en) | Therapeutic agents | |
ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
ATE423122T1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
IL180495A (en) | Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors | |
EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |